Probi (OM:PROB) - Stock Price, News & Analysis

PROB Stock Overview

Researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally.

About the company

PROB fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	4/6
Past Performance	1/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 10% below our estimate of its fair value

Earnings are forecast to grow 50.01% per year

Risk Analysis

Profit margins (2.1%) are lower than last year (3.2%)

Probi AB (publ) Competitors

BioInvent International

OM:BINV

SEK 2.7b

Devyser Diagnostics

OM:DVYSR

SEK 1.9b

Egetis Therapeutics

OM:EGTX

SEK 1.7b

Cereno Scientific

OM:CRNO B

SEK 1.6b

Price History & Performance

Summary of all time highs, changes and price drops for Probi
Historical stock prices
Current Share Price	SEK 269.00
52 Week High	SEK 319.00
52 Week Low	SEK 171.50
Beta	0.47
11 Month Change	-9.43%
3 Month Change	28.71%
1 Year Change	46.20%
33 Year Change	-43.55%
5 Year Change	-7.08%
Change since IPO	652.45%

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Recent updates

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Jul 24

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Jun 26

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 19% Below Its Share Price

May 05

Is Probi AB (publ)'s (STO:PROB) Recent Price Movement Underpinned By Its Weak Fundamentals?

Mar 05

Here's Why I Think Probi (STO:PROB) Might Deserve Your Attention Today

Feb 15

Here's What Probi AB (publ)'s (STO:PROB) Shareholder Ownership Structure Looks Like

Jan 29

Probi AB (publ)'s (STO:PROB) Intrinsic Value Is Potentially 20% Below Its Share Price

Jan 11

Have Insiders Been Buying Probi AB (publ) (STO:PROB) Shares?

Dec 22

Has Probi AB (publ)'s (STO:PROB) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Dec 03

Shareholder Returns

	PROB	SE Biotechs	SE Market
7D	-1.1%	-6.1%	-0.6%
1Y	46.2%	21.0%	17.0%

Return vs Industry: PROB exceeded the Swedish Biotechs industry which returned 20.5% over the past year.

Return vs Market: PROB exceeded the Swedish Market which returned 18.4% over the past year.

Price Volatility

Is PROB's price volatile compared to industry and market?
PROB volatility
PROB Average Weekly Movement	7.8%
Biotechs Industry Average Movement	8.7%
Market Average Movement	5.7%
10% most volatile stocks in SE Market	12.1%
10% least volatile stocks in SE Market	3.3%

Stable Share Price: PROB has not had significant price volatility in the past 3 months.

Volatility Over Time: PROB's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1991	162	Anita Johansen	www.probi.com

Probi AB (publ) researches, manufactures, and sells probiotics for dietary supplements and food companies in North America, South America, Europe, Sweden, the Middle East, Africa, Asia Pacific, and internationally. The company conducts research primarily in the fields of mental, digestive, immune, bone, oral, children’s, women’s, and senior health, as well as iron absorption. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, chilled diary and plant based products, frozen desserts and ice-cream, powder formulas, and recovery drinks.

Probi AB (publ) Fundamentals Summary

How do Probi's earnings and revenue compare to its market cap?
PROB fundamental statistics
Market cap	SEK 3.07b
Earnings (TTM)	SEK 13.70m
Revenue (TTM)	SEK 642.71m

223.7x

P/E Ratio

4.8x

P/S Ratio

Is PROB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PROB income statement (TTM)
Revenue	SEK 642.71m
Cost of Revenue	SEK 431.37m
Gross Profit	SEK 211.33m
Other Expenses	SEK 197.63m
Earnings	SEK 13.70m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Oct 22, 2024

Earnings per share (EPS)	1.20
Gross Margin	32.88%
Net Profit Margin	2.13%
Debt/Equity Ratio	0%

How did PROB perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

108%

Payout Ratio

PROB Stock Overview

Rewards

Risk Analysis

Probi AB (publ) Competitors

OM:BINV

SEK 2.7b

OM:DVYSR

SEK 1.9b

OM:EGTX

SEK 1.7b

OM:CRNO B

SEK 1.6b

Price History & Performance

Recent News & Updates

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Recent updates

Probi's (STO:PROB) Anemic Earnings Might Be Worse Than You Think

Second quarter 2024 earnings released: EPS: kr0.71 (vs kr0.55 loss in 2Q 2023)

Probi AB (publ) Strengthens the Gut-Brain Offering with New Study in Older Adults

There's No Escaping Probi AB (publ)'s (STO:PROB) Muted Revenues Despite A 43% Share Price Rise

Probi AB (publ) Approves Election of Stephanie Blum Sperisen as Board Member

Now 22% undervalued

Now 22% undervalued

Full year 2023 earnings: EPS exceeds analyst expectations

Now 21% undervalued

Dividend of kr1.30 announced

Now 21% undervalued after recent price drop

Probi AB (publ) to Report Fiscal Year 2024 Results on Jan 28, 2025

Full year 2023 earnings: EPS exceeds analyst expectations

Probi AB (Publ) Proposes Dividend for the Fiscal Year 2023

Probi AB (publ) to Report Q3, 2024 Results on Oct 22, 2024

Probi AB (publ), Annual General Meeting, May 07, 2024

Third quarter 2023 earnings released: EPS: kr0.56 (vs kr1.09 in 3Q 2022)

Probi AB (Publ) Appoints Per Lindblad as New CFO, Effective from 1st of November, 2023

Probi Launches Two New Concepts Together with Clasado Biosciences at Supply Side West

Second quarter 2023 earnings released: kr0.55 loss per share (vs kr1.75 profit in 2Q 2022)

Probi AB (Publ) Announces Resignation of Henrik Lundkvist as Chief Financial Officer

Insufficient new directors

Upcoming dividend of kr1.30 per share at 0.7% yield

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) to Report Fiscal Year 2022 Final Results on Apr 04, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (Publ) Proposes Dividend for the 2022 Financial Year, Payable on May 11, 2023

Now 24% undervalued after recent price drop

Now 20% undervalued after recent price drop

Probi AB (publ) to Report Q2, 2023 Results on Jul 18, 2023

Now 21% undervalued after recent price drop

Probi AB (publ) Announces Management Changes

Now 25% undervalued after recent price drop

Probi Probiotics Reduce Gut Problems in Connection with Cancer Radiotherapy

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Probi AB (publ) Provides Earnings Guidance for the Third Quarter of 2022

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Probi AB (Publ) Approves Dividend for the Financial Year 2021

Chief Executive Officer recently bought kr409k worth of stock

Upcoming dividend of kr1.30 per share

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend, Payable on 12 May 2022

Now 23% undervalued after recent price drop

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Probi AB (Publ) Proposes Dividend for the Year 2021

Third quarter 2021 earnings released: EPS kr1.62 (vs kr2.91 in 3Q 2020)

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Should You Be Adding Probi (STO:PROB) To Your Watchlist Today?

Estimating The Intrinsic Value Of Probi AB (publ) (STO:PROB)

Consensus EPS estimates fall to kr8.37

Second quarter 2021 earnings released: EPS kr1.39 (vs kr2.37 in 2Q 2020)

Investor sentiment improved over the past week

Is Now The Time To Put Probi (STO:PROB) On Your Watchlist?